Brief: Biophytis says €11.1M Of Available Cash & Equivalents On Dec 31, 2022
18/04/2023 17:26
April 18 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS- €11.1M OF AVAILABLE CASH & EQUIVALENTS ON DEC 31, 2022 FINANCING INSTRUMENTS
FOR
TOTAL €22M ALLOWING FINANCIAL VISIBILITY BEYOND MID 2024
* BIOPHYTIS SA - POSITIVE RESULTS OF THE PHASE 2-3 COVA STUDY FOR THE TREATMENT OF SEVERE
COVID-19
WITH SARCONEOS (BIO101)
Source text - https://bit.ly/3A9L9dW
Further company coverage: ALBPS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon